|Articles|August 6, 2014

Risk and Innovation in Biopharma: A CEO’s Perspective

In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.

In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.

Click here for the article.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

ByNicholas Jacobus

December 4th 2025

Risk and Innovation in Biopharma: A CEO’s Perspective

Newsletter

Related Content

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trending on PharmExec

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

Five Steps for Successful CGT Commercialization Through Health Systems Partnerships

Patients Avoid Care as Healthcare Costs Rise: Report

Report: Richard Pazdur Out as Director of CDER